作者
K Sumida, Y Ubara, J Hoshino, K Mise, N Hayami, T Suwabe, M Kawada, A Imafuku, R Hiramatsu, E Hasegawa, M Yamanouchi, N Sawa, K Takaichi
发表日期
2016/4
期刊
Osteoporosis International
卷号
27
页码范围
1441-1450
出版商
Springer London
简介
Summary
Once-weekly 56.5-μg teriparatide treatment was significantly associated with the increase in lumbar spine bone mineral density at 48 weeks among hemodialysis patients with hypoparathyroidism and low bone mass; however, discontinuation of treatment because of adverse events was frequently observed. Careful monitoring for adverse events should be required.
Introduction
Once-weekly 56.5-μg teriparatide is reportedly effective for treating osteoporotic patients without renal insufficiency. However, little is known about the efficacy and safety of once-weekly teriparatide in hemodialysis patients.
Methods
We conducted a 48-week prospective, observational cohort study including 22 hemodialysis patients aged 20 years or older with hypoparathyroidism and low bone mass who received once-weekly …
学术搜索中的文章
K Sumida, Y Ubara, J Hoshino, K Mise, N Hayami… - Osteoporosis International, 2016